Senseonics Holdings Inc

senseonics.com

What Do They Do?

Sells implantable glucose-monitoring systems for people with diabetes, through distributors and healthcare professionals.

How Do They Make Money?

Sales to distributors and U.S. fulfillment partners generate revenue when they take delivery of Eversense systems and supplies; U.S. consignment sales generate revenue when a patient uses the product.

FY2025 revenue

Who Are Their Customers?

Senseonics sells mainly to distributors and U.S. fulfillment partners, which supply prescribed products to healthcare providers and patients and bill insurers. It also sells on consignment through healthcare professionals.

Customers above 10% of revenue, FY2025

of revenue from one customer

FY2024: 82% from one customer

How Are They Changing?

Since the FY2025 annual report

Latest quarter: Q2 FY2026, the three months to Jun 30, 2026

Revenue: ▲ +118%; vs $6.6M in Q2 FY2025
Net income: ▲ +153% (Loss); vs −$14.5M in Q2 FY2025

Aug 6, 2026 Raised 2026 revenue and gross-margin guidance Revenue guidance rose to $62 million to $66 million from $60 million to $64 million.
Jun 8, 2026 Completed purchases of Eversense commercial assets in Europe Transfers for Germany, Spain and Sweden closed June 1; Italy closed June 8.

Growing. Revenue grew 2.6x in 4 years, from $13.7M in FY2021 to $35.3M in FY2025, about 27% a year.

Commercial operations Earlier, Ascensia held exclusive worldwide distribution rights and handled sales and marketing; the latest report says Senseonics took over U.S. commercial responsibility and began marketing and distribution with its own sales force, while Ascensia's European rights became non-exclusive.

Who Do They Compete With?

Competes with Dexcom, Medtronic, Abbott, Roche Diagnostics, and Ascensia

Comments